Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

作者
Suzanne Trudel,Meral Beksac,Luděk Pour,Sosana Delimpasi,Vladimir Vorobyev,Hang Quach,Ivan Špıčka,Jakub Radocha,Paweł Robak,Kihyun Kım,Michèle Cavo,Kazuhito Suzuki,S. Yousuf Zafar,Ainslee Moore,Michael Duggan,Kristin Morris,Amy Phillips-Jones,Margaret Polinkovsky,Jayleen Grams,Ianire Garrobo-Calleja
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 2264-2264
标识
DOI:10.1182/blood-2025-2264
摘要

Abstract Introduction: Triplet or quadruplet regimens, combining proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies, are standard of care for newly diagnosed multiple myeloma (MM); however, most patients (pts) eventually experience relapse. At first relapse, there remains a lack of effective treatment options that have durable outcomes and are accessible for all pts, particularly those who have been exposed to or have disease refractory to lenalidomide and/or anti-CD38 monoclonal antibodies. In the phase 3 DREAMM-8 trial (NCT04484623) in pts with relapsed/refractory MM (RRMM) who had received ≥1 prior line of treatment including lenalidomide, belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) significantly improved progression-free survival (PFS; median follow-up, 21.8 months; hazard ratio [HR], 0.52; 95% CI, 0.37-0.73; P<0.001) vs pomalidomide, bortezomib, and dexamethasone (PVd), a standard of care in this population. Here, we report long-term follow-up from the DREAMM-8 trial to better characterize the durability of BPd treatment benefit. Methods: As previously reported, pts who had received ≥1 prior line of therapy including lenalidomide were randomized 1:1 to receive BPd or PVd. Treatment continued until progressive disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurred first. Efficacy assessments occurred every 4 weeks in the intention-to-treat population. The primary endpoint was PFS; secondary endpoints included overall survival, independent review committee–assessed response rates, minimal residual disease (MRD)–negative status, duration of response (DOR), PFS2 (ie, time from randomization to disease progression or death from any cause after initiation of new antimyeloma therapy), and safety. Results: Overall, 302 pts were randomized to receive BPd (n=155) or PVd (n=147). At the data cutoff (July 7, 2025), median follow-up was 35.8 months (range, 0.03-56.5 months). Median PFS (95% CI) with BPd vs PVd was 32.6 months (21.1 months-not reached [NR]) vs 12.5 months (9.1-17.6 months), respectively (HR, 0.49; 95% CI, 0.36-0.67). BPd led to a substantial benefit in response depth, with a complete response or better (≥ CR) reported in 43% (67/155) of pts receiving BPd vs 17% (25/147) receiving PVd. Moreover, pts treated with BPd achieved ≥ CR MRD negativity at almost 5 times the rate observed in those receiving PVd (28% [43/155] vs 6% [9/147]). MRD negativity was durable, with 15% (24/155) of pts in the BPd arm having ≥ CR MRD negativity sustained for ≥12 months, compared with 3% (4/147) in the PVd arm. Consistent with the reported depth of response, responses with BPd were durable, with a median DOR (partial response or better; 95% CI) that was NR (29.5 months-NR) with BPd vs 16.4 months (11.1-22.5 months) with PVd; the proportion of pts with a 24-month DOR was 65% (95% CI, 55%-73%) vs 40% (95% CI, 29%-50%), respectively. PFS benefit was maintained following subsequent antimyeloma therapy, with a median PFS2 (95% CI) of 47.1 months (28.4 months-NR) in pts receiving BPd vs 21.7 months (13.8-28.6 months) in those receiving PVd (HR, 0.52; 95% CI, 0.38-0.70). Follow-up for overall survival is ongoing. Overall, grade 3/4 adverse events (AEs) and fatal serious AEs were experienced by 91% (136/150) and 14% (21/150) of pts in the BPd arm, respectively, compared with 74% (108/145) and 13% (19/145) of pts in the PVd arm; AEs leading to permanent discontinuation of any treatment component occurred in 22% (33/150) of pts receiving BPd vs 14% (21/145) receiving PVd. Conclusions: After extended follow-up of the DREAMM-8 trial,BPd led to a substantial increase in response depth and durability vs PVd in a population of pts with RRMM, most of whom had lenalidomide-refractory disease and a quarter of whom had disease refractory to anti-CD38 monoclonal antibodies. The updated safety profile of BPd was broadly consistent with the primary analysis. BPd resulted in a median PFS of >30 months and a maintained PFS benefit following subsequent antimyeloma therapy; as a combination that can be easily administered in the outpatient setting, these results support BPd as a potential new standard of care in RRMM. Funding statement: GSK (study ID 207499).Drug-linker technology licensed from Seagen Inc; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Wiki发布了新的文献求助30
刚刚
hh完成签到,获得积分10
1秒前
2秒前
小博士328完成签到,获得积分10
2秒前
3秒前
高大真完成签到,获得积分10
3秒前
852的应助被Marshall采纳,获得10
4秒前
酷波er的应助被Marshall采纳,获得10
4秒前
4秒前
桐桐的应助被霸气雯采纳,获得10
7秒前
iwhisper完成签到,获得积分10
7秒前
7秒前
Xx完成签到,获得积分20
8秒前
桐桐的应助被热心宛菡采纳,获得10
8秒前
ki发布了新的文献求助10
8秒前
orixero的应助被停云采纳,获得10
8秒前
kjh完成签到,获得积分10
10秒前
小唐人完成签到,获得积分10
10秒前
11秒前
大卫和小草完成签到,获得积分10
11秒前
丘比特的应助被怪力花生采纳,获得30
11秒前
斯文败类的应助被xuxu采纳,获得50
11秒前
水煮电吹风的应助被Xx采纳,获得10
12秒前
master发布了新的文献求助10
13秒前
小马甲的应助被runrun采纳,获得10
14秒前
研友_LkqbzZ发布了新的文献求助10
14秒前
隋玉发布了新的文献求助10
14秒前
Owen的应助被runrun采纳,获得10
14秒前
SciGPT的应助被runrun采纳,获得10
14秒前
Akim的应助被runrun采纳,获得10
14秒前
FashionBoy的应助被runrun采纳,获得10
14秒前
14秒前
彭于晏的应助被runrun采纳,获得10
14秒前
kk子的应助被runrun采纳,获得10
15秒前
15秒前
小马甲的应助被runrun采纳,获得10
15秒前
Gibson发布了新的文献求助10
15秒前
斯文败类的应助被runrun采纳,获得10
15秒前
汉堡包的应助被runrun采纳,获得10
15秒前
ZZZ完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485